Moneycontrol PRO

business

Don't see immediate revenue impact from Quark deal: Biocon

Biocon has inked a pact with California-based Quark Pharma to co-develop medicines based on the emerging siRNA technology.

first published: Dec 20, 2013 11:30 am

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347